+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome



Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome



Clinical Reviews in Allergy and Immunology 39(3): 160-165



Recurrent fetal loss affects 1-5% of women of childbearing age. Immunological mechanisms may account for 40% of recurrent miscarriages, and in particular, the antiphospholipid syndrome (APS) appears to be implicated in 7-25% of the cases. Because antiphospholipid (aPL) antibodies have thrombogenic properties, fetal loss in patients with APS has been ascribed to thrombosis of placental vessels. However, we have shown that inflammation, specifically activation of complement with generation of the anaphylotoxin C5a, is an essential trigger of fetal injury. Thrombosis and inflammation are linked in many clinical conditions. Tissue factor (TF), the major cellular initiator of the coagulation protease cascade, plays important roles in both thrombosis and inflammation, and its expression is increased in patients with APS. Here we describe how TF, acting as a proinflammatory molecule, induces trophoblast injury and fetal death in a mouse model of APS. Importantly, we will discuss how TF contributes to C5a-induced oxidative burst in neutrophils leading to trophoblasts and fetal injury in APS. The finding that TF is an important effector in aPL-induced inflammation may allow the development of new therapies to abrogate the inflammatory loop caused by tissue factor and improve pregnancy outcomes in patients with aPL antibodies. Statins downregulate TF-induced inflammation and rescued the pregnancies in aPL-treated mice, suggesting they may be a good treatment for women with aPL-induced pregnancy complications.

(PDF emailed within 0-6 h: $19.90)

Accession: 055614896

Download citation: RISBibTeXText

PMID: 19921475

DOI: 10.1007/s12016-009-8187-1


Related references

The role of tissue factor in the antiphospholipid syndrome. Arthritis and Rheumatism 44(11): 2467-2476, 2001

Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus 19(4): 370-378, 2010

A role for the tissue factor pathway in the pathogenesis of the antiphospholipid syndrome. Australian Journal of Medical Science 28(3): 99-107, 2007

The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thrombosis and Haemostasis 79(2): 276-281, 1998

The role of tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thrombosis & Haemostasis 79(2): 276-281, 1998

Thrombosis in primary antiphospholipid syndrome: A pivotal role for monocyte tissue factor expression. Arthritis and Rheumatism 40(5): 834-841, 1997

Tissue Factor overexpression in platelets of patients with Antiphospholipid Syndrome: induction role of anti-β2-GPI antibodies. Clinical and Experimental Immunology 2018, 2018

Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus 14(2): 129-136, 2005

FRI0425The Global Antiphospholipid Syndrome Score (GAPSS) Differentiates Between Transient Ischemic Attack and Stroke in Patients with Antiphospholipid Antibodies. Annals of the Rheumatic Diseases 74(Suppl 2): 581.1-581, 2015

Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis and Rheumatism 54(1): 301-311, 2005

Tissue factor in the antiphospholipid syndrome. Lupus 17(10): 952-958, 2008

Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden. Blood Coagulation and Fibrinolysis 18(6): 559-564, 2007

Tissue factor pathway and the antiphospholipid syndrome. Journal of Autoimmunity 15(2): 217-220, 2000

Immunological attack by adult cells in the developing chick embryo: influence of the vascularity of the host spleen and of homograft rejection by the embryo on splenomegaly. Journal of Embryology and Experimental Morphology 11: 119-134, 1963

Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. Journal of Clinical Investigation 118(10): 3453-3461, 2008